Article
Medicine, General & Internal
Marianne Kiszka-Kanowitz, Klaus Theede, Sandra Bohn Thomsen, Jacob Tveiten Bjerrum, Jorn Brynskov, Ida Benedikte Gottschalck, Elena Akimenko, Karen Lisa Hilsted, Anders Neumann, Signe Wildt, Lone Larsen, Jens Kristian Munk, Per Holger Ibsen, Huma Gul Rehana Janjua, Lise Lotte Gluud, Anette Mertz-Nielsen
Summary: The study suggests that combination therapy of low-dose azathioprine and allopurinol may be more effective in achieving steroid- and infliximab-free clinical remission in patients with moderate-to-severe UC compared to azathioprine monotherapy.
Article
Gastroenterology & Hepatology
Julian Panes, Severine Vermeire, Marla C. Dubinsky, Edward V. Loftus, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Jean-Frederic Colombel
Summary: In patients with ulcerative colitis, re-treatment with tofacitinib can effectively and safely recapture efficacy, regardless of prior treatment failure. Specific efficacy data show that a substantial proportion of patients can achieve clinical response and remission with tofacitinib re-treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Elizabeth Parody-Rua, Maria Chaparro
Summary: This systematic review concludes that ustekinumab has shown efficacy, effectiveness, and safety for the treatment of ulcerative colitis, as demonstrated in randomized controlled trials (and their extension studies) as well as real clinical practice observational studies.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Maria T. Abreu, David S. Rowbotham, Silvio Danese, William J. Sandborn, Ye Miao, Hongyan Zhang, Ilia Tikhonov, Remo Panaccione, Tadakazu Hisamatsu, Ellen J. Scherl, Rupert W. Leong, Ramesh P. Arasaradnam, Waqqas Afif, Laurent Peyrin-Biroulet, Bruce E. Sands, Colleen Marano
Summary: The study confirms the efficacy of ustekinumab in treating patients with ulcerative colitis for up to 3 years, and no new safety issues were observed.
JOURNAL OF CROHNS & COLITIS
(2022)
Review
Plant Sciences
Juntao Yin, Lunshou Wei, Naiqin Wang, Xiumin Li, Mingsan Miao
Summary: Curcumin as an adjuvant therapy for ulcerative colitis may be effective in inducing clinical remission, but its effects on other outcomes are controversial. Appropriate dosage, formulation, longer treatment duration, and topical medication may have a greater potential advantage.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Hyo Jong Kim, Byong Duk Ye, Shoko Arai, Masato Hoshi, Hirotoshi Yuasa, Junichi Tabira, Shigeyuki Toyoizumi, Nanzhi Shi, Joon-suk Woo, Toshifumi Hibi
Summary: This study presents safety and efficacy data of tofacitinib for the treatment of ulcerative colitis in East Asian patients. The results show that the safety and efficacy of tofacitinib are consistent with the global study population, although the occurrence rate of herpes zoster is slightly higher in East Asian patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
A. Buisson, M. Nachury, M. Bazoge, C. Yzet, P. Wils, M. Dodel, D. Coban, B. Pereira, M. Fumery
Summary: Switching from intravenous to subcutaneous infliximab can reduce the long-term risk of relapse in patients with inflammatory bowel disease. Close monitoring and dose escalation should be recommended for patients receiving different doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Rebecca J. Gordon, Reeder Wells, Camille Johansen, Shanshan Liu, Suzanne E. Dahlberg, Scott B. Snapper, Paul A. Rufo
Summary: This study assessed the efficacy and safety of high-dose, interval cholecalciferol administration in IBD patients receiving infliximab. The results showed that cholecalciferol supplementation was well-tolerated, but high doses were required for patients with IBD to achieve vitamin D sufficiency.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2022)
Article
Gastroenterology & Hepatology
William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes
Summary: This study provides a summary of tofacitinib safety in the treatment of ulcerative colitis. The results showed a low incidence of adverse events, with stable rates in patients treated for at least 7.8 years. The incidence rates of important safety events were generally below 2.0, except for herpes zoster.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Oncology
Ruth Gabriela Herrera-Gomez, Miruna Grecea, Claire Gallois, Valerie Boige, Patricia Pautier, Barbara Pistilli, David Planchard, David Malka, Michel Ducreux, Olivier Mir
Summary: This study retrospectively evaluated the safety and efficacy of combining bevacizumab and chemotherapy in adult cancer patients with inflammatory bowel disease. The results showed that the combination treatment was safe in patients with quiescent or moderately active inflammatory bowel disease.
Review
Medicine, General & Internal
Yaling Tong, Yunfeng Yu, Shuang Yin, Shanzhi Lin, Yun Chen, Xuan Su
Summary: This study systematically evaluated the clinical efficacy and safety of acupoint application in the treatment of ulcerative colitis. It found that acupoint application can effectively improve the clinical comprehensive efficacy, syndrome efficacy, and interleukin-4 levels, while reducing interferon-gamma levels. The conclusion is that acupoint application is a safe and effective method for the treatment of ulcerative colitis.
Article
Medicine, General & Internal
Marta Vernero, Cristina Bezzio, Davide G. Ribaldone, Stefania Costa, Davide Scalvini, Elisa Tribocco, Gianpiero Manes, Simone Saibeni
Summary: This study evaluated the effectiveness and safety of GP2017, a biosimilar drug, in the treatment of inflammatory bowel disease (IBD). The results showed that GP2017 is an effective and safe therapy for IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
William J. Sandborn, Brian G. Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J. Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C. Wolf, Geert D'Haens
Summary: The study examined the long-term safety and efficacy of Ozanimod in patients with moderately to severely active ulcerative colitis, showing continued benefits in clinical response, endoscopic improvement, and biomarker measures with 1 mg daily dosage. The high rate of study participation and long-term benefit indicates the potential of Ozanimod as a treatment option for UC patients.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Gastroenterology & Hepatology
Nicholas E. Burr, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: In a network meta-analysis, upadacitinib 45 mg once daily ranked first for clinical remission in all patients, patients naive to anti-TNF-alpha drugs and patients previously exposed. Infliximab 10 mg/kg ranked first for endoscopic improvement. Most drugs were safe and well tolerated.
Article
Gastroenterology & Hepatology
Makoto Naganuma, Taku Kobayashi, Reiko Kunisaki, Katsuyoshi Matsuoka, Shojiro Yamamoto, Ami Kawamoto, Daisuke Saito, Kosaku Nanki, Kazuyuki Narimatsu, Hisashi Shiga, Motohiro Esaki, Shinichiro Yoshioka, Shingo Kato, Masayuki Saruta, Shinji Tanaka, Eriko Yasutomi, Kaoru Yokoyama, Kei Moriya, Yoshikazu Tsuzuki, Makoto Ooi, Mikihiro Fujiya, Atsushi Nakazawa, Takayuki Abe, Tadakazu Hisamatsu, Japanese UC Study Grp
Summary: Most first-use advanced therapies were effective for patients with acute severe ulcerative colitis, while second-use advanced therapies might have had limited benefits in inducing clinical remission. These findings may provide insights for the management of hospitalized patients.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Kang Chao, Xueding Wang, Qian Cao, Jiaming Qian, Kaichun Wu, Xia Zhu, Hong Yang, Jie Liang, Lang Lin, Zicheng Huang, Yu Zhang, Yibiao Huang, Yinghao Sun, Xianmin Xue, Min Huang, Pinjin Hu, Ping Lan, Xiang Gao
INFLAMMATORY BOWEL DISEASES
(2017)
Article
Rheumatology
Huaxia Yang, Yinghao Sun, Lidan Zhao, Xuan Zhang, Fengchun Zhang
CLINICAL RHEUMATOLOGY
(2018)
Article
Oncology
Y. H. Sun, J. Li, H. J. Shu, Z. L. Li, J. M. Qian
CLINICAL & TRANSLATIONAL ONCOLOGY
(2019)
Article
Respiratory System
Min Peng, Hua Meng, Yinghao Sun, Yu Xiao, Hong Zhang, Ke Lv, Baiqiang Cai
JOURNAL OF THORACIC DISEASE
(2019)